Genentech USA Inc - Company Profile
Powered by 
All the data and insights you need on Genentech USA Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Genentech USA Inc Strategy Report
- Understand Genentech USA Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Genentech USA Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
1 DNA Way, South San Francisco, California, 94080
Website
www.gene.com
Telephone
1 650 2251000
No of Employees
14,000
Industry
Pharmaceuticals and Healthcare
Genentech USA Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Biooncology: | Actemra |
| Alecensa (alectinib) | Activase |
| Avastin (bevacizumab) | Alecensa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Orionis Biosciences for challenging targets in major disease areas, including oncology and neurodegeneration. |
| 2023 | Regulatory Approval | In May, the company announced the Acceptance of Application for Vabysmo for the treatment of retinal vein occlusion. |
| 2023 | Regulatory Approval | In April, the company announced that FDA had approved its Polivy Combination with R-CHP for people with certain types of untreated diffuse large B-Cell Lymphoma. |
Competitor Comparison
| Key Parameters | Genentech USA Inc | Amgen Inc | Biogen Inc | Amphastar Pharmaceuticals Inc | Cellectar Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | Thousand Oaks | Cambridge | Rancho Cucamonga | Florham Park |
| State/Province | California | California | Massachusetts | California | New Jersey |
| No. of Employees | 14,000 | 26,700 | 7,570 | 1,761 | 20 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas Schinecker | Chairman | Executive Board | - | - |
| Levi Garraway | Executive Vice President; Chief Medical Officer; Head- Product Development | Executive Board | - | - |
| Aviv Regev | Executive Vice President - Genentech Research and Early Development | Executive Board | - | - |
| Ashley Magargee | Chief Executive Officer | Senior Management | 2024 | - |
| Ed Harrington | Chief Financial Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward